Endocrine effects in the hazard assessment of drugs used in animal production

Journal of Experimental and Clinical Cancer Research

Volumn 21, Issue 4, 2002, Pages 445-456

  Mantovani, Alberto ^a   Macri A ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Endocrine disrupters; Hazard identification; Hormones; Imidazoles; Mechanisms of action; Nitroimidazoles; Regulatory toxicology; Steroids

Indexed keywords

DIMETRIDAZOLE; ENILCONAZOLE; IMIDAZOLE DERIVATIVE; IPRONIDAZOLE; KETOCONAZOLE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; PARCONAZOLE; RONIDAZOLE; UNCLASSIFIED DRUG;

ANIMAL HUSBANDRY; BREAST CARCINOGENESIS; CARCINOGENICITY; DRUG SAFETY; GENOTOXICITY; NONHUMAN; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; STEROID METABOLISM; TESTIS;

ANIMAL EXPERIMENTATION; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HORMONES; HUMANS; IMIDAZOLES; MALE;

EID: 0036990428     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Anadon A., Martinez-Larranaga M.R., Martinez M.A: Scientific basis and regulatory aspects for the toxicology of plant protection products in the European Union. Vet. Hum. Toxicol. 43: 297-301, 2001.
2. Macri A., Mantovani A.: The safety evaluation of residues of veterinary drugs in farm animal tissues and products. J. Experim. Clin. Cancer Res. 14: 119-129, 1995.
3. European Agency for the Evaluation of Medicinal Products. http://www.emea.eu.int/htms/vet/mrls. Maximum Residue Limits. Summary Reports.
4. Ostergaard G., Knudsen I.: The applicability of the ADI (Acceptable Daily Intake) for food additives to infants and children. Food Add. Contam. 15(suppl.): 63-74, 1998.
5. Mantovani A., Stazi A.V., Maranghi F., Macri' C., Ricciardi C.: Problems in testing and risk assessment of endocrine disrupting chemicals with regard to developmental toxicology. Chemosphere 24: 1293-1300, 1999.
6. Goldman J.M., Laws S.C., Balchak S.K., Cooper R.L., Kavlock R.J.: Endocrine-disrupting chemicals: prepubertal exposures and effects on sexual maturation and thyroid activity in the female rat. A focus on the EDSTAC recommendations. Crit. Rev. Toxicol. 30: 135-196, 2000.
7. Neubert D.: Vulnerability of the endocrine system to xenobiotic influence. Regul. Toxicol. Pharmacol. 26: 9-29, 1997.
8. Rakissky V.N., Koblyakov V.A., Turasov V.S.: Nongenotoxic (epigenetic) carcinogens: pesticides as an example. A critical review. Teratog. Carcinog. Mutagen. 20: 229-240, 2000.
9. European Agency for the Evaluation of Medicinal Products. http://www.emea.eu.int/htms/vet/mrls/Dimetridazole.
10. World Health Organization. Antiprotozoal Agents. In: Toxicological Evaluation of Certain Veterinary Drug Residues in Foods. Geneva: WHO Food Additives Series, 1990, 25: 32-74.
11. European Agency for the Evaluation of Medicinal Products. http://www.emea.eu.int/htms/vet/mrls/Metronidazole.
12. European Agency for the Evaluation of Medicinal Products. http://www.emea.eu.int/htms/vet/mrls/Ronidazole.
13. Lamp K.C., Freeman C.D., Klutman N.E., Lacy M.K.: Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin. Pharmacokin. 36: 353-373, 1999.
14. Caro-Paton T., Carvajal A., Martin de Diego I., Martin-Arias L.H., Alvarez Requejo A., Rodriguez Pinilla E.: Is metronidazole teratogenic? A meta-analysis. Brit. J. Clinical Pharmacol. 44: 179-182, 1997.
15. Sorensen H.T., Larsen H., Jensen E.S., Thulstrup A.M., Schonheyder H.C., Nielsen G.L., Czeizel A.: Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J. Antimicrob. Chemother. 44: 854-856, 1999.
16. Diav-Citrin O., Shechtman S., Gotteiner T., Arnon J., Ornoy A.: Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology 63: 186-192, 2001.
17. Thapa P.B., Whitlock J.A., Brockman Worrell K.G., Gideon P., Mitchel E.F. Jr., Roberson P., Pais R., Ray W.A.: Prenatal exposure to metronidazole and risk of childhood cancer: a retrospective cohort study of children younger than 5 years. Cancer 83: 1461-1468, 1998.
18. Berbel-Tornero O., Lopez-Andreu J.A., Ferris-Tortajada J.: Prenatal exposure to metronidazole and risk of childhood cancer: a retrospective cohort study of children younger than 5 years. Cancer 85: 2494-2495, 1999.
19. Bone W., Jones N.G., Kamp G., Yeung C.H., Cooper T.G.: Effect of ornidazole on fertility of male rats: inhibition of a glycolysis-related motility pattern and zona binding required for fertilization in vitro. J. Reprod. Fertil. 118: 127-135.
20. Mudry M.D., Martinez-Flores I., Palermo A.M., Carballo M.A., Egozcue J., Garcia Caldes M.: Embryolethality induced by metronidazole (MTZ) in Rattus norvegicus. Teratog. Carcinog. Mutagen. 21: 197-205, 2001.
21. Grover J.K., Vats V., Srinivas M., Das S.N., Jha P., Gupta D.K., Mitra D.K.: Effect of metronidazole on spermatogenesis and FSH, LH and testosterone levels of pre-pubertal rats. Indian J. Exp. Biol. 39: 1160-1162, 2001.
22. Cavaliere A., Bacci M., Vitali R.: Induction of mammary tumors with metronidazole in female Sprague-Dawley rats. Tumori 70: 307-311, 1984.
23. Rustia M., Shubik P.: Experimental induction of hepatomas, mammary tumors, and other tumors with metronidazole in noninbred Sas:MRC(WI)BR rats. J. Natl Cancer Inst., 63: 863-868, 1979.
24. Bendesky A., Menendez D., Ostrosky-Wegman P.: Is metronidazole carcinogenic? Mutat. Res. 511: 133-144, 2002.
25. Medina D., Peterson L.E., Moraes R., Gay J.: Short-term exposure to estrogen and progesterone induces partial protection against N-nitroso-N-methylurea-induced mammary tumorigenesis in Wistar-Furth rats. Cancer Lett. 169: 1-6, 2001.
26. Thordarson G., Van Horn K., Guzman R.C., Nandi S., Talamantes F.: Parous rats regain high susceptibility to chemically induced mammary cancer after treatment with various mammotropic hormones. Carcinogenesis 22: 1027-1033, 2001.
27. Takahashi M., Iizuka S., Watanabe T., Yoshida M., Ando J., Wakabayashi K., Maekawa A.: Possible mechanisms underlying mammary carcinogenesis in female Wistar rats by nitrofurazone. Cancer Lett. 156: 177-184, 2000.
28. O'Connor J.C., Plowchalk D.R., Van Pelt C.S., Davis L.G., Cook J. C.: Role of prolactin in chloro-S-triazine rat mammary tumorigenesis. Drug Chem. Toxicol. 23: 575-601, 2000.
29. Stalla G.K., Stalla J., von Werder K., Muller O.A., Gerzer R., Hollt V., Jakobs K.H.: Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology 125: 699-706, 1989.
30. Favaretto A.L., Antunes-Rodrigues J., Vieira C.L., LamanoCarvalho T.L.: Pituitary-testicular axis in benznidazole-treated rats. Brazil. J. Med. Biol. Res. 23: 719-722, 1990.
31. Purba H.S., Back D.J., Breckenridge A.M.: Inhibition of estrogen 2-hydroxylase. J. Steroid Biochem. 24: 1091-1093, 1986.
32. Jager L.P., De Graaf G.J., Widjaja-Greefkes H.C., AccordBurleson C.C., Van den Dungen H.M., Baars A.J.: Effects of feed additives and veterinary drugs on aldosterone production and release by porcine adrenal cells in vitro. J. Veter. Pharmacol. Therap. 17: 175-185, 1994.
33. Fagan T.C., Johnson D.G., Grosso D.S.: Metronidazole-induced gynecomastia. JAMA 254: 3217, 1985.
34. Aizawa H., Niimura M., Kon Y.: Influence of oral metronidazole on the endocrine milieu and sebum excretion rate. J. Dermatol. 19: 959-963, 1992.
35. Mason J.I., Carr B.R., Murry B.A.: Imidazole antimycotics: selective inhibitors of steroid aromatization and progesterone hydroxylation. Steroids 50: 179-189, 1987.
36. European Agency for the Evaluation of Medicinal Products. http://www.emea.eu.int/htms/vet/mrls/Enilconazole.
37. European Agency for the Evaluation of Medicinal Products. http://www.emea.eu.int/htms/vet/mrls/Parconazole.
38. Tanaka T.: Reproductive and neurobehavioral effects of imazalil administered to mice. Reprod. Toxicol. 9: 281-288, 1995.
39. Marty M.S., Crissman J.W., Carney E.W.: Evaluation of the male pubertal onset assay to detect testosterone and steroid biosynthesis inhibitors in CD rats. Toxicol. Sci. 60: 285-295, 2001.
40. Venkatakrishnan K., von Moltke L.L., Greenblatt D.J.: Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokin. 38: 111-180, 2000.
41. O'Connor J.C., Cook J.C., Slone T.W., Makovec G.T., Frame S.R., Davis L.G.: An ongoing validation of a Tier I screening battery for detecting endocrine-active compounds (EACs). Toxicol. Sci. 46: 45-60, 1998.
42. Ashby J., Lefevre P.A.: The peripubertal male rat assay as an alternative to the Hershberger castrated male rat assay for the detection of anti-androgens, oestrogens and metabolic modulators. J. Appl. Toxicol. 20: 35-47, 2000.
43. Gray L.E.Jr., Wolf C., Lambright C., Mann P., Price M., Cooper R.L., Ostby J.: Administration of potentially antiandrogenic pesticides (procymidone, linuron, iprodione, chlozolinate, p,p′-DDE, and ketoconazole) and toxic substances (dibutyland diethylhexyl phthalate, PCB 169, and ethane dimethane sulphonate) during sexual differentiation produces diverse profiles of reproductive malformations in the male rat. Toxicol. Ind. Health 15: 94-118, 1999.
44. Cummings A.M., Hedge J.L., Laskey J.: Ketoconazole impairs early pregnancy and the decidual cell response via alterations in ovarian function. Fundam. Appl. Toxicol. 40: 238-246, 1999.
45. Marty M.S., Crissman J.W., Carney E.W.: Evaluation of the EDSTAC female pubertal assay in CD rats using 17 beta-estradiol, steroid biosynthesis inhibitors, and a thyroid inhibitor. Toxicol. Sci. 52: 269-277, 1999.
46. Lu Z., Xia G., Byskov A.G., Andersen C.Y.: Effects of amphotericin B and ketoconazole on mouse oocyte maturation: implications on the role of meiosis-activating sterol. Mol. Cell. Endocrinol. 164: 191-196, 2000.
47. Morishita K., Okumura H., Ito N., Takahashi N.: Primary culture system of adrenocortical cells from dogs to evaluate direct effects of chemicals on steroidogenesis. Toxicology 165: 171-178, 2001.
48. Johansson M.K., Sanderson J.T., Lund B.O.: Effects of 3-MeSO(2)-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol. In Vitro 16: 113-121, 2002.
49. Wilson V.S., LeBlanc G.A.: The contribution of hepatic inactivation of testosterone to the lowering of serum testosterone levels by ketoconazole. Toxicol. Sci. 54: 128-137, 2000.
50. Hayes F.J., DeCruz S., Seminara S.B., Boepple P.A., Crowley W.F. Jr.: Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. J. Clin. Endocrinol. Metab. 86: 53-58, 2001.
51. Eagling V.A., Tjia J.F., Back D.J.: Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 45: 107-114, 1998.
52. Gal M., Eldar-Geva T., Margalioth E.J., Barr I., Orly J., Diamant Y.Z.: Attenuation of ovarian response by low-dose ketoconazole during superovulation in patients with polycystic ovary syndrome. Fertil. Steril. 72: 26-31, 1999.
53. Weber M.M., Will A., Adelmann B., Engelhardt D.: Effect of ketoconazole on human ovarian C17,20-desmolase and aromatase. J. Steroid Biochem. Mol. Biol. 38: 213-218, 1991.
54. Weber M.M., Lang J., Abedinpour F., Zeilberger K., Adelmann B., Engelhardt D.: Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis. Clin. Investig. 71: 933-938, 1993.
55. Murphy B.E., Ghadirian A.M., Dhar V.: 1998, Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy. Canad. J. Psych. 43: 279-286, 1998.
56. Comby F., Lagorce J.F., Buxeraud J., Raby C.: Antithyroid action of ketoconazole: in-vitro studies and rat in-vivo studies. J. Pharm. Pharmacol. 46: 50-53, 1994.
57. Kohan S.L., Guillen C.E., Pardes E.M., Junco M., Soto R.J., Sartorio G.C.: Effects of ketoconazole on the iodide uptake by FRTL-5 cells. Acta Endocrinol. (Copenhaghen) 127: 449-453, 1992.
58. Vinggaard A.M., Breinholt V., Larsen J.C.: Screening of selected pesticides for oestrogen receptor activation in vitro. Food Add. Contamin. 16: 533-542, 1999.
59. Vinggaard A.M., Hnida C., Breinholt V., Larsen J.C.: Screening of selected pesticides for inhibition of CYP19 aromatase activity in vitro. Toxicol. In Vitro 14: 227-234, 2000.
60. Muto N., Hirai H., Tanaka T., Itoh N., Tanaka K.: Induction and inhibition of cytochrome P450 isoforms by imazalil, a food contaminant, in mouse small intestine and liver. Xenobiotica 27: 1215-1223, 1997.
61. Doody K.M., Murry B.A., Mason J.I.: The use of rat Leydig tumor (R2C) and human hepatoma (HEPG2) cells to evaluate potential inhibitors of rat and human steroid aromatase. J. Enzyme Inhib. 4: 153-158, 1990.
62. New. M.I.: Steroid 21-hydroxylase deficiency (congenital adrenal hyperplasia). Am. J. Med.: 16(98-1A): 2S-8S, 1995.
63. Bilezikian J.P., Morishima A., Bell J., Grumbach M.M.: Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N. Engl. J. Med. 339: 599-603, 1998.
64. Medina D., Sivaraman L., Hilsenbeck S.G., Conneely O., Ginger M., Rosen J., Omalle B.W.: Mechanisms of hormonal prevention of breast cancer. Ann. N. Y. Acad. Sci. 952: 23-35, 2001
65. Wislocki P.G., Lu A.Y.: Formation and biological evaluation of ronidazole bound residues. Drug Metab. Rev. 22: 649-661, 1990.
66. Ashby J.: Validation of in vitro and in vivo methods for assessing endocrine disrupting chemicals. Toxicol. Pathol. 28: 432-437, 2000.
67. Gray L.E. Jr. Tiered screening and testing strategy for xenoestrogens and antiandrogens. Toxicol. Lett. 102-103: 677-680, 1998.
68. DeVito M., Biegel L., Brouwer A., Brown S., Brucker-Davis F., Cheek A.O., Christensen R., Colborn T., Cooke P., Crissman J., Crofton K., Doerge D., Gray E., Hauser P., Hurley P., Kohn M., Lazar J., McMaster S., McClain M., McConnell E., Meier C., Miller R., Tietge J., Tyl R.: Screening methods for thyroid hormone disruptors. Environ. Health Perspect. 107: 407-415, 1999.
69. Andersen H.R., Vinggaard A.M., Rasmussen T., Gjermandsen I.M., Bomefeld-Jorgensen C.E.: Effects of currently used pesticides in assays for estrogenicity, androgenicity, and aromatase activity in vitro. Toxicol. Appl. Pharmacol. 179: 1-12, 2002.
70. Pennie W. D., Woodyatt N.J., Aldridge T.C., Orphanides G.: 2001: Application of genomics to the definition of the molecular basis for toxicity. Toxicol. Lett. 120: 353-358, 2001.
71. Waring J.F., Ciurlionis R., Jolly R.A., Heindel M., Ulrich R. G.: Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120: 359-368, 2001.